TheraCryf PLC (TCF)

Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

0.19p

Buy

0.20p

arrow-up0.00p (+0.00%)

Prices updated at 14 Aug 2026, 16:24 BST
| Prices minimum 15 mins delay
|
Prices in GBX
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 ...
FTSE All-Share
arrow-down-0.17%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
our Investment Fees and Charges.

logo In the news

Sharecast service unavailable

logo Press releases

24 Jun 2026

15 May 2026

14 May 2026

16 Apr 2026

14 Apr 2026

26 Jan 2026

05 Jan 2026

18 Dec 2025

03 Dec 2025

26 Nov 2025

logo Key dates

Forecast date
Half yearly resultsDec 2026
Annual general meetingAug 2026
Final results-
Annual report-
Previous date
Final resultsAug 2026
Annual reportAug 2026
Half yearly resultsDec 2025
Annual general meetingJul 2025

logo Company reports

31 Mar 2023
Annual Report doc-arrow-d
30 Sep 2025
Quarterly Report doc-arrow-d


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.